


# PRODUCT INFORMATION



## Nemonapride

Item No. 21376

**CAS Registry No.:** 75272-39-8  
**Formal Name:** *rel*-5-chloro-2-methoxy-4-(methylamino)-N-[(2R,3R)-2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]-benzamide  
**Synonym:** YM-09151-2  
**MF:** C<sub>21</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub>  
**FW:** 387.9  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 212, 282, 308 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Nemonapride is supplied as a crystalline solid. A stock solution may be made by dissolving the nemonapride in the solvent of choice, which should be purged with an inert gas. Nemonapride is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of nemonapride in ethanol and DMSO is approximately 10 mg/ml and approximately 20 mg/ml in DMF.

Nemonapride is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, nemonapride should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Nemonapride has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Nemonapride is an antipsychotic that readily passes through the blood brain barrier and exhibits potent neuroleptic effects in animals.<sup>1</sup> It binds dopamine 2 (D<sub>2</sub>)-like receptors preferentially over D<sub>1</sub>-like receptors (K<sub>i</sub>s = 0.06, 0.3, and 0.15 nM for D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub>, respectively).<sup>1,2</sup> Nemonapride also binds sigma 1 (σ<sub>1</sub>) and σ<sub>2</sub> receptors (K<sub>i</sub>s = 8.4 and 9.6 nM, respectively) and activates the serotonin 1A receptor (5-HT<sub>1A</sub>; IC<sub>50</sub> = 34 nM).<sup>3,4</sup>

### References

1. Terai, M., Usuda, S., Kuroiwa, I., *et al.* Selective binding of YM-09151-2, a new potent neuroleptic, to D<sub>2</sub>-dopaminergic receptors. *Jpn. J. Pharmacol.* **33**(4), 749-755 (1983).
2. Seeman, P. and H. H. M. Van Tol. Dopamine receptor pharmacology. *Trends Pharmacol. Sci.* **15**(7), 264-270 (1994).
3. Ujike, H., Akiyama, K., and Kuroda, S. [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes. *Neuroreport* **7**(5), 1057-1061 (1996).
4. Assié, M.-B., Cosi, C., and Koek, W. 5-HT<sub>1A</sub> receptor agonist properties of the antipsychotic, nemonapride: Comparison with bromerguride and clozapine. *Eur. J. Pharmacol.* **334**(2-3), 141-147 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)